Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

키워드

참고문헌 (10)

1. 이승민, "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways", Clinical and Molecular Hepatology, 28(4), pp.827~840 (2022), 대한간학회
2. Hwangbo H, "Auranofin attenuates non-alcoholic fatty liver disease by suppressing lipid accumulation and NLRP3 inflammasome-mediated hepatic inflammation in vivo and in vitro", Antioxidants(Basel), 9, pp.1040~ (2020)
3. Cox AR, "The rheumatoid arthritis drug auranofin lowers leptin levels and exerts antidiabetic effects in obese mice", Cell Metab, 34, pp.1932~1946 (2022)
4. Qiao JT, "Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease", Metabolism, 81, pp.13~24 (2018)
5. Glanz A, "Autophagic degradation of IRF3 induced by the small-molecule auranofin inhibits its transcriptional and proapoptotic activities", J Biol Chem, 297, pp.101274~ (2021)
6. Yang L, "Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms", Signal Transduct Target Ther, 5, pp.138~ (2020)
7. Lee D, "Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma", Hepatology, 69, pp.1768~1786 (2019)
8. Wang S, "An overview of ferroptosis in non-alcoholic fatty liver disease", Biomed Pharmacother, 153, pp.113374~ (2022)
9. Chen J, "The multifaceted role of ferroptosis in liver disease", Cell Death Differ, 29, pp.467~480 (2022)
10. Lippmann J, "Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma", Transl Oncol, 13, pp.100785~ (2020)